We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+6.08%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$42.8B
AUM Growth
+$3.35B
Cap. Flow
+$1.35B
Cap. Flow %
3.15%
Top 10 Hldgs %
14.82%
Holding
2,894
New
39
Increased
2,631
Reduced
168
Closed
44

Top Buys

Rank Stock Value
1
ABT icon
Abbott
ABT
+$21.8M
2
CVX icon
Chevron
CVX
+$20.5M
3
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$19.7M
4
INCY icon
Incyte
INCY
+$17.8M
5
XOM icon
ExxonMobil
XOM
+$16.9M

Top Sells

Rank Stock Value
1
SE
Spectra Energy Corp Wi
SE
+$49.6M
2
STJ
St Jude Medical
STJ
+$41.1M
3
LLTC
Linear Technology Corp
LLTC
+$30.3M
4
HAR
Harman International Industries
HAR
+$13.8M
5
ENH
Endurance Specialty Holdings Ltd
ENH
+$10.3M

Sector Composition

Rank Sector Weight
1 Financials 16.2%
2 Technology 15.06%
3 Healthcare 13.05%
4 Industrials 10.88%
5 Consumer Discretionary 9.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TVIA
2801
DELISTED
TerraVia Holdings, Inc. Common Stock
TVIA
$70K ﹤0.01%
96,120
+3,683
+4% +$3.43K
TTNP
2802
DELISTED
Titan Pharmaceuticals
TTNP
$69K ﹤0.01%
6
+2
+50% +$28.1K
MN
2803
DELISTED
MANNING & NAPIER, INC.
MN
$69K ﹤0.01%
12,108
+696
+6% +$4.58K
VHI icon
2804
Valhi
VHI
$389M
$68K ﹤0.01%
1,718
+98
+6% +$3.98K
RELY
2805
DELISTED
Real Industry, Inc.
RELY
$68K ﹤0.01%
23,832
-3,175
-12% -$15.7K
APVO icon
2806
Aptevo Therapeutics
APVO
$4.96M
– –
0
– –
FLNT
2807
Fluent
FLNT
$106M
$63K ﹤0.01%
2,249
+119
+6% +$2.7K
CVRS
2808
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
$63K ﹤0.01%
48,260
+17,633
+58% +$14.4K
LFVN icon
2809
LifeVantage
LFVN
$80.1M
$62K ﹤0.01%
11,551
-1,852
-14% -$11.7K
DCOY
2810
Decoy Therapeutics
DCOY
$2.14M
– –
0
– –
RCKT icon
2811
Rocket Pharmaceuticals
RCKT
$343M
$60K ﹤0.01%
7,456
+3,000
+67% +$20.2K
NDLS icon
2812
Noodles & Co
NDLS
$95.1M
$59K ﹤0.01%
+1,273
New +$42.9K
TOVX icon
2813
Theriva Biologics
TOVX
$10.1M
$59K ﹤0.01%
11
+4
+57% +$27.9K
PMTS icon
2814
CPI Card Group
PMTS
$239M
$56K ﹤0.01%
2,684
+196
+8% +$4.44K
TPST icon
2815
Tempest Therapeutics
TPST
$14.3M
$56K ﹤0.01%
10
-2
-17% -$9.31K
AXSM icon
2816
Axsome Therapeutics
AXSM
$11.7B
$53K ﹤0.01%
+13,688
New +$65.4K
CYTR
2817
DELISTED
CytRx Corp
CYTR
$53K ﹤0.01%
20,060
+9,990
+99% +$25.3K
NIHD
2818
DELISTED
NII Holdings, Inc. Common Stock
NIHD
$53K ﹤0.01%
40,600
-12,307
-23% -$26.6K
GNMX
2819
DELISTED
Aevi Genomic Medicine Inc
GNMX
$52K ﹤0.01%
28,185
+1,274
+5% +$5.76K
LPCN icon
2820
Lipocine
LPCN
$17.1M
$51K ﹤0.01%
773
+36
+5% +$2.33K
ABCD
2821
DELISTED
Cambium Learning Group, Inc.
ABCD
$51K ﹤0.01%
+10,310
New +$51.5K
AST
2822
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$51K ﹤0.01%
14,908
+858
+6% +$3.34K
IBRX icon
2823
ImmunityBio
IBRX
$7.15B
$50K ﹤0.01%
14,143
-2,459
-15% -$12.2K
ALT icon
2824
Altimmune
ALT
$568M
$43K ﹤0.01%
177
+5
+3% +$2.67K
CRDF icon
2825
Cardiff Oncology
CRDF
$63M
$43K ﹤0.01%
516
+170
+49% +$23.1K
111 112
113
114 115

Similar funds

VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $123B AUM 34.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

RhumbLine Advisers's Q1 2017 Portfolio in Review

As of Q1 2017, RhumbLine Advisers held 2,894 positions worth $42.8B, up 8.5% from $39.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.

RhumbLine Advisers deployed $1.35B of net new capital in Q1 2017, opening 39 new positions and adding to 2,631 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.

By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was Biogen, an estimated $8.21M trimmed.

  • RhumbLine Advisers's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
  • RhumbLine Advisers added most to Abbott in Q1 2017, an estimated $21.8M increase.
  • RhumbLine Advisers's biggest Q1 2017 reduction was Biogen, cutting an estimated $8.21M.
  • RhumbLine Advisers fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $49.6M.
  • RhumbLine Advisers's ten largest holdings make up 15% of its $42.8B portfolio in Q1 2017.
  • RhumbLine Advisers opened 39 new positions and closed 44 in Q1 2017.
  • RhumbLine Advisers's portfolio value rose 8.5% quarter-over-quarter to $42.8B.

Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.